hrp0082p1-d3-167 | Growth (2) | ESPE2014

Aromatase Inhibitors in Girls: Anastrazole Combined to an LHRH Analogue is a Safe and Effective Strategy in Girls with Early or Precocious Puberty with Compromised Growth Potential

Papadimitriou Dimitrios T , Dermitzaki Eleni , Papaevangelou Vassiliki , Papadimitriou Anastasios

Background: Third generation aromatase inhibitors have been used to increase predicted adult height (PAH) in boys but in girls only in McCune–Albright syndrome.Objective and hypotheses: We overcame the theoretical concern of secondary hyperandrogenism by combining anastrazole to an LHRH analogue in a 6-year prospective study to test whether the combination therapy could significantly improve PAH compared to inhibition of puberty alone.<p class="...

hrp0092p1-16 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Normocalcemic Hyperparathyroidism in Children

Papadimitriou Dimitrios T. , Dermitzaki Eleni , Kleanthous Kleanthis , Papadimitriou Anastasios , Mastorakos George

Normocalcemic primary hyperparathyroidism (NPHPT) has been recognized as a variant of primary hyperparathyroidism (PHPT) and it is characterized by elevated PTH with persistently normal concentrations of albumin-adjusted total and ionized calcium. It is related to increased risk in development of osteopenia/osteoporosis as well of parathyroid adenoma and hypercalcemia/hypercalciuria. In order to identify biochemical disorders of PTH in normocalcemic children we performed in al...

hrp0092p3-301 | Late Breaking Abstracts | ESPE2019

A novel heterozygous mutation in the SLC5A2 gene causing mild failure to thrive and subclinical hypoglycemia in a 2-year old girl

Dermitzaki Eleni , Manolakos Emmanouil , Filiousi Fotini , Kleanthous Kleanthis , Papadimitriou Dimitrios T.

Patients: A 2-year old girl was referred due to glucosuria 1874 mg/dl. Fasting blood sugar was 71 mg/dl and HbA1c 4.8%. Examination of her growth charts revealed mild failure to thrive, since 15 months of age, as far as weight gain and height velocity. We used Flash technology (FreeStyle Libre) to identify hypoglycemic episodes. In 9 days, 8% of the time was < 70 mg/dl, with 11 hypoglycemic events: mean duration 94 min, lowest 52 mg/dl.<p class...

hrp0089rfc13.4 | Pituitary, Neuroendocrinology and Puberty 2 | ESPE2018

Gain in Predicted Adult Height Using the Combination of an LHRH Analogue and an Aromatase Inhibitor in Early Maturing Girls with Compromised Growth for 2 yrs or Until the Age of 11 is Maintained and Further Improved by Aromatase Inhibitor Monotherapy: Results on Final Height of the ‘GAIL’ Study ISRCTN11469487

Papadimitriou Dimitrios T , Dermitzaki Eleni , Papagianni Maria , Kleanthous Kleanthis , Attilakos Achilleas , Mastorakos George , Papadimitriou Anastasios

Background: Third generation aromatase inhibitors (AI) have never been used as monotherapy to increase predicted adult height (PAH) in girls. Our previously published GAIL study (J Endocrinol Invest. 2016 Apr;39(4):439–46) has shown that the combination of anastrozole to an LHRH analogue for 24 months is safe and effective in ameliorating PAH in girls with early puberty +1.21 SDS (+7.51 cm) compared to inhibition of puberty alone +0.31 SDS (+1.92 cm), P=...

hrp0089p2-p290 | Multisystem Endocrine Disorders P2 | ESPE2018

Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year Old Girl

Bothou Christina , Alexopoulos Alexis , Dermitzaki Eleni , Kleanthous Kleanthis , Papadimitriou Anastasios , Mastorakos George , Papadimitriou Dimitrios T

Atopic dermatitis (AD) is a chronic inflammatory disease affecting children and adolescence. The traditional therapeutic options for AD, including emollients topically and immune modulatory agents systemically focusing on reducing skin inflammation and restoring the function of the epidermal barrier, are proven ineffective in many cases. Several studies have linked vitamin D supplementation with either a decreased risk to develop AD or a clinical improvement of the symptoms of...

hrp0089p1-p201 | Pituitary, Neuroendocrinology and Puberty P1 | ESPE2018

Anastrozole is Safe as Monotherapy in Early Maturing Girls with Compromised Growth, Further Improving Gain in Predicted Adult Height by the Initial Combination Therapy of an LHRH Analogue and an Aromatase Inhibitor: Results from the ‘Gail’ Study ISRCTN11469487

Dermitzaki Eleni , Kleanthous Kleanthis , Papagianni Maria , Attilakos Achilleas , Mastorakos George , Papadimitriou Anastasios , Papadimitriou Dimitrios T

Background: Third generation aromatase inhibitors (AI) have never been used as monotherapy, except for Mc Cune-Albright syndrome and autonomous ovarian cysts, to increase predicted adult height (PAH) in girls, mainly due to the theoretical concern of hyperandrogenism. Our previously published GAIL study [J Endocrinol Invest. 2016 Apr;39(4):439–46] has shown that the combination of anastrozole to an LHRH analogue for 24 months is safe and effective in ameliorating PAH in g...

hrp0089lb-p16 | Late Breaking P1 | ESPE2018

Successful Treatment of Alopecia Totalis with Calcitriol and Paricalcitol in Two Girls Aged 3 and 7-Years

Papadimitriou Dimitrios T , Bothou Christina , Dermitzaki Eleni , Kleanthous Kleanthis , Karkavitsas Konstantinos , Mastorakos George , Papadimitriou Anastasios

Backgound: Alopecia areata (AA) or Alopecia Totalis (AT) is an autoimmune disease directed at the hair follicle, either limited to patchy hair loss over the scalp (focalis), or as total loss of scalp hair (totalis) or as total loss of both scalp and body hair (universalis). Management can be challenging, and despite multiple treatment modalities, no therapy still stands. While localized AA may respond well to topical corticosteroids, many patients require more aggressive secon...

hrp0086p2-p63 | Adrenal P2 | ESPE2016

The Evolution of Bone Age in Girls with Premature Adrenarche

Marakaki Chrysanthi , Theodoropoulou Sophia , Papadimitriou Dimitrios T , Dermitzaki Eleni , Papadimitriou Anastasios

Background: In premature adrenarche (PA) children bone age (BA) may be greater than chronological age (CA), however final height is usually within target height (TH).Objective and hypotheses: Aim of the study was to evaluate the evolution of BA in girls with PA.Method: We studied retrospectively the files of 60 girls with PA followed in our unit. Anthropometric data and Tanner pubertal status were determined in each visit and BA wa...

hrp0097p1-228 | Diabetes and Insulin | ESPE2023

Secondary PREvention of Diabetes Type 1 with oral CALcitriol and analogs, the PRECAL study

T. Papadimitriou Dimitrios , Dermitzaki Eleni , Christopoulos Panagiotis , Papagianni Maria , Kleanthous Kleanthis , Papadimitriou Anastasios , Mastorakos George

Type 1 diabetes (T1D) hits about 1:300 with rising incidence affecting increasingly younger children. Population screening at ages 2-6yrs with T1D associated autoantibodies (T1Ab) has been recently proven sensitive. While potential treatments to prevent or delay T1D are currently in development, a population based cost-effective preventive strategy is still lacking. Hence, 2000IU cholecalciferol daily in a large birth cohort study published in 2001 reduced by 80% the risk of T...

hrp0098p2-313 | Late Breaking | ESPE2024

Correlation of Bone Health Index (BHI) and Metacarpal Index (MCI) with calcium metabolism parameters in children and adolescents

Ntova Maria , Chrysis Dionysios , Dermitzaki Eleni , N Michoula Aspasia , Christopoulos Panayiotis , Mastorakos George , N Grivea Ioanna , T Papadimitriou Dimitrios

Introduction: The assessment of bone maturation with artificial intelligence (AI) has introduced new straightforward indicators of bone health monitoring related the much more complex and expensive method of measuring bone density with DEXA (Dual-Energy X-Ray Absorptiometry). Bone Health Index (BHI) describes bone mass as a function of cortical thickness, width and length of the three middle metacarpals, using digital hand X-rays for bone age evaluation from D...